PRL and schizophrenia: Additionally, the analysis of three placebo-controlled RCTs indicated comparable withdrawal rates for aripiprazole (10.1%) and placebo (11.5%), emphasizing that, according to the available evidence, the primary consideration for reducing prolactin concentrations in schizophrenia patients with hyperprolactinemia is the addition of aripiprazole.